ArticleThe Journal of biological chemistry2025
The cobalamin processing enzyme of Trichoplax adhaerens.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cobalamin (Cbl) is an essential cofactor for methionine synthase and methylmalonyl-CoA mutase, but it must first undergo chemical processing for utilization in animals. In humans, this processing comprises β-axial ligand cleavage and Cbl reduction and is performed by the enzyme MMACHC (HsCblC). Although the functionality of CblC is well-understood in higher-order organisms, little is known about the evolutionary origin of these enzymes and the reactivity of CblCs in lower-order organisms with unique environmental and cellular conditions. Therefore, we investigated the CblC of Trichoplax adhaerens (TaCblC), a marine organism considered to be one of the earliest evolutionarily diverging and simplest living animals. The TaCblC sequence contained conserved residues important for Cbl processing in higher-order organisms. The predicted structure of TaCblC closely resembled known CblC structures and had features consistent with Cbl and cosubstrate binding capabilities. Recombinantly expressed TaCblC could bind and process several Cbl analogues using glutathione or NADH as cosubstrates, similarly to previously characterized CblCs, but with variable rates and dependencies on the presence of oxygen. Notably, TaCblC dealkylates methylcobalamin at a rate ca. 2-times higher than HsCblC, although this comes with a lower ratio of product to glutathione oxidation, suggesting higher unproductive electron transfer in the TaCblC system. This reflects differences in cellular conditions of the more ancient homologue, which lives in low oxygen levels and an environment of low Cbl bioavailability (∼2 pm in sea water).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.